Savara Inc (NASDAQ:SVRA) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP decreased its holdings in Savara Inc (NASDAQ:SVRA - Free Report) by 36.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,481,654 shares of the company's stock after selling 3,142,358 shares during the quarter. Wellington Management Group LLP owned about 3.19% of Savara worth $16,829,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rosalind Advisors Inc. acquired a new stake in Savara in the fourth quarter worth about $8,151,000. Emerald Advisers LLC acquired a new stake in Savara in the 4th quarter worth approximately $7,161,000. JPMorgan Chase & Co. grew its position in Savara by 1,948.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,423,139 shares of the company's stock worth $4,369,000 after purchasing an additional 1,353,649 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Savara by 238.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company's stock valued at $3,865,000 after purchasing an additional 642,259 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Savara by 15.7% in the third quarter. State Street Corp now owns 4,138,276 shares of the company's stock worth $17,546,000 after buying an additional 560,242 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Stock Performance

Shares of SVRA traded down $0.02 during mid-day trading on Monday, reaching $2.90. The company had a trading volume of 16,448 shares, compared to its average volume of 1,331,433. The stock has a market capitalization of $500.64 million, a P/E ratio of -6.74 and a beta of 0.52. Savara Inc has a 52-week low of $2.26 and a 52-week high of $5.31. The stock has a 50 day moving average of $2.72 and a two-hundred day moving average of $3.12. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). The firm had revenue of $0.27 million for the quarter. On average, analysts expect that Savara Inc will post -0.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on SVRA. HC Wainwright reissued a "buy" rating and issued a $6.00 target price on shares of Savara in a research report on Friday, March 28th. Wells Fargo & Company assumed coverage on Savara in a research note on Friday, December 20th. They set an "overweight" rating and a $8.00 price target on the stock. Finally, JMP Securities restated a "market outperform" rating and issued a $9.00 price objective on shares of Savara in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $8.83.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.